Kenneth Custer, executive vice president and president, Lilly Cardiometabolic Health, said: “The SURPASS-CVOT results show ...

Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary endpoints in patients with relapsed or refractory ...

Eli Lilly and Company and the UK Government have announced a joint programme to develop innovative models of care for obesity ...

Teva Pharmaceuticals has received US FDA approval for AJOVY (fremanezumab-vfrm) as a preventive treatment for episodic migraine in children and adolescents aged 6–17 who weigh at least 45 kilograms.

Sever Pharma Solutions has deepened its partnership with Silo Pharma to advance a novel ketamine-based implant designed to ...

Despite the outcome, VE202 was well tolerated. Most adverse events were mild or moderate, with no reports of treatment-related serious adverse events. Further analyses on bacterial colonisation and ...

Everest Medicines has announced a strategic equity investment of US$30.9 million in I-Mab, acquiring 15,846,154 newly issued ...

Eli Lilly and Company has announced positive topline results from its phase 3 BRUIN CLL-314 trial of Jaypirca (pirtobrutinib) ...

Nxera Pharma has launched a broad proprietary pipeline focused on next-generation therapies for obesity and related metabolic ...

Eli Lilly has announced positive topline results from its phase 3 SURPASS-CVOT trial, comparing Mounjaro (tirzepatide) with Trulicity (dulaglutide) in adults with type 2 diabetes and cardiovascular ...